Chemomab Therapeutics annual stock-based compensation
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Chemomab Therapeutics Stock-Based Compensation Growth & History (CMMB)
Chemomab Therapeutics's stock-based compensation was $623,000 for fiscal 2025.
View full Chemomab Therapeutics company overviewChemomab Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $623,000 | $6,000 | +0.97% |
| 2024 | 2024-12-31 | $617,000 | −$874,000 | −58.62% |
| 2023 | 2023-12-31 | $1.5M | −$1.7M | −53.57% |
| 2022 | 2022-12-31 | $3.2M | $1.2M | +59.04% |
| 2021 | 2021-12-31 | $2.0M | $1.9M | +1453.08% |
| 2020 | 2020-12-31 | $130,000 | −$1.0M | −88.77% |
| 2019 | 2019-12-31 | $1.2M | −$768,000 | −39.88% |
| 2018 | 2018-12-31 | $1.9M | $1.2M | +175.14% |
| 2017 | 2017-12-31 | $700,000 | $430,000 | +159.26% |
| 2016 | 2016-12-31 | $270,000 | — | — |
Chemomab Therapeutics quarterly stock-based compensation
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2023 | 2023-06-30 | $639,000 | −$122,000 | −16.03% |
| Q1 2023 | 2023-03-31 | $484,000 | −$390,000 | −44.62% |
| Q4 2022 | 2022-12-31 | $740,000 | −$268,000 | −26.59% |
| Q3 2022 | 2022-09-30 | $836,000 | $395,000 | +89.57% |
| Q2 2022 | 2022-06-30 | $761,000 | $234,000 | +44.40% |
| Q1 2022 | 2022-03-31 | $874,000 | $831,000 | +1932.56% |
| Q4 2021 | 2021-12-31 | $1.0M | $975,000 | +2954.55% |
| Q3 2021 | 2021-09-30 | $441,000 | $418,000 | +1817.39% |
| Q2 2021 | 2021-06-30 | $527,000 | $499,000 | +1782.14% |
| Q1 2021 | 2021-03-31 | $43,000 | −$3,000 | −6.52% |
| Q4 2020 | 2020-12-31 | $33,000 | −$56,000 | −62.92% |
| Q3 2020 | 2020-09-30 | $23,000 | −$298,000 | −92.83% |
| Q2 2020 | 2020-06-30 | $28,000 | −$340,000 | −92.39% |
| Q1 2020 | 2020-03-31 | $46,000 | −$334,000 | −87.89% |
| Q4 2019 | 2019-12-31 | $89,000 | — | — |
| Q3 2019 | 2019-09-30 | $321,000 | — | — |
| Q2 2019 | 2019-06-30 | $368,000 | — | — |
| Q1 2019 | 2019-03-31 | $380,000 | — | — |
Chemomab Therapeutics stock-based compensation trends
Over the last five fiscal years, Chemomab Therapeutics's stock-based compensation increased from $130,000 to $623,000, a change of $493,000. The latest reported quarter, Q2 2023, shows $639,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Chemomab Therapeutics source filings ↗